No deal might be the best outcome for dividend-seeking investors. It’s a story as old as time. Two Dividend Aristocrats meet, ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently.

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...